Name of Mechanism Indications Contraindication Side Effects Nursing

Drug of Action Responsibilities

Generic Magnesium  To  Parenteral CNS: Before:
Name: Sulfate is prevent administrati drowsiness  Take an
Magnesium essential / on , depress appropriate
Sulfate element for control contraindica reflexes, seizure precaution.
muscle and seizure ted inpatient placid
Brand nerve in pre- with heart paralysis, During:
Name: transmission. eclamp block hypotherm  Check
Magnesium Extracellular sia myocardial ia Magnesium
Sulfate fluid damage. CV: level repeat
levels:1.5  To hypotensio doses.
Dosage: – manage  Use n, flushing Disappeara
>Preeclampsi 2.5 mg/L. Mg preter cautiously bradycardi nce of knee,
a depresses m inpatients a, Jerl and
woman: 4g the CNS and labor. with circulatory patellar
IV in 250mL controls impaired collapse, reflexes is a
D5W with convulsion by renal depress sign of
normal blocking function. cardiac impeding
saline and 4- release of function magnesium
5 g. deep IM acetylcholine  Use Skin: toxicity.
into buttock at the cautiously in diaphoresis
alternate in myoneural pregnant  Monitor
every 4hrs., junction. woman urine intake
P.R.N 4g I.V. Also, mg during labor. and output.
Lodding dose decrease
then 1-2 q sensitivity of After:
hr. as I.V motor end
 Observe
infusion. plate to
neonates
Dose should acetylcholine
for signs of
not exceed and
magnesium
30-40 g. daily decreases the
toxicity.
excitability of
the mother
membrane.
Classification
as a laxative
:
it acts in the
Anticonvulsa
small and
nt
large
intestine to
attract and
retain water
in the
intestinal
lumen,
increasing
intraluminal
pressure, also
releases
cholecystokin
in
Drug Name Dosages Therapeutic Indications Adverse Contraindicati Nursing
Actions effects ons Responsibilities
Generic Drug: PO Betamethaso Systemic Sodium and Hypersensitivi Assessment
Betamethasone Allergic and ne is a administration fluid ty; systemic
inflammatory corticosteroi retention, fungal or  History
Brand Name: disorders; d with mainly  Hypercal potassium acute (Systemic
Celestone, congenital glucocorticoi cemia and calcium infections administration):
Celestone adrenal d activity. It associate depletion. Infections, fungal
Soluspan, hyperplasia prevents and d with Muscle infections,
Betaject, 0.5-5mg/day. by controlling cancer wasting, amebiasis, vaccinia
Betamethasone IM the rate of  Short- weakness, and varicella, and
IM/PO Allergic and protein term osteoporosi antibiotic-resistant
inflammatory synthesis, manage s.GI infections; kidney
Classification: disorders as depressing ment of disturbance or liver disease;
Corticosteroids betamethasone the migration inflamm s and hypothyroidism;
Na phosphate of atory bleeding. ulcerative colitis
and polymorphon and Increased with impending
betamethasone uclear allergic appetite perforation;
acetate: leukocytes disorders and delayed diverticulitis; active
Initial:0.25-9 and , such as wound or latent peptic
mg/day in1-2 fibroblasts, rheumat healing; ulcer;
divided doses. and reversing oid hirsutism, inflammatory
Ophth Allergic capillary arthritis, bruising, bowel disease;
and permeability collagen striae, acne; CHF; hypertension;
inflammatory and diseases raised thromboembolic
conditions of lysosomal (eg, SLE), intracranial disorders;
the eye as 0.1% stabilization. dermatol pressure, osteoporosis;
soln: As Na ogic headache, seizure disorders;
phosphate: diseases depression, diabetes mellitus;
Instill 1-2 hrly (eg, psychosis, lactation
until symptoms pemphig menstrual
are controlled. us), irregularitie  Physical:
As0.1% oint: status s. Baseline weight, T,
As Na asthmati Hyperglyce reflexes and grip
phosphate: cus, and mia, strength, affect
Apply2-4 autoimm DM. and orientation, P,
times/day or at une Suppression BP, peripheral
night w/ the disorders of pituitary- perfusion,
eyedrops. adrenocorti prominence of
Topical Skin  Hematol cal axis. superficial veins,
disorders As ogic Growth Rand adventitious
dipropionate disorders retardation sounds, serum
(0.05%) or : in children electrolytes, blood
valerate (0.025 Thrombo (prolonged glucose
or 0.1%): Apply cytopeni therapy).
as directed a Increased Interventions
purpura, susceptibilit
erythrobl y for Systematic use
astopeni infections.
a Topical use:  Give daily
Dermal dose 9am
 Ulcerativ atrophy, to mimic
e colitis, local normal
acute irritation, peak
exacerba folliculitis, corticoste
tions of hypertricho roid blood
MS, and sis. levels.
palliation Inhalation:  Increase
in some Hoarseness, dosage
leukemia candidiasis when
s and of mouth patient is
lympho and subject to
mas throat. stress
Topical  Taper
 Trichinos application doses
is with to the eye: when
neurolog Corneal discontinu
ic or ulcers, ing high
myocardi raised IOP dose or
al and reduced long-term
involvem visual therapy
ent acuity.
 Do not
Intradermal
give live
injection:
virus
Local
vaccines
hypopigmen
with
tation of
immunos
deeply
uppressiv
pigmented
e doses of
skin. Intra-
corticoste
articular
roids.
injection:
Joint
Topical
damage,
dermatologic
fibrosis, esp.
preparations
in load
bearing
joints Examine area for
infections and
skin integrity
before application

 Administ
er
cautiousl
y to
pregnant
patients’
topical
corticost
eroids
have
caused
teratoge
nic
effects
and can
be
absorbed
from
systemic
site.